undamentalytics Newsletter
Sign in

Prelude Therapeutics Inc income statement

In fiscal 2025, Prelude Therapeutics Inc reported revenue of $12.1m, up 73.4% on the year before, operating income of −$105m (a -861.3% margin) and net income of −$99.5m, or −$1.29 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2024Dec 20242025Dec 2025LTMJun 2026
Revenue71222
Research and development1189469
General and administrative292220
Operating income−140−105−67
Income tax00—
Net income−127−99−60
Diluted EPS−$1.68−$1.29−$0.72
Diluted shares (average)76m77m84m
EBITDA−138−103−66

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: JANX vs PRLDCRSP vs PRLDABEO vs PRLD

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Prelude Therapeutics Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Prelude Therapeutics Inc.